Preventing conversion of donor-specific anti-HLA antibodies (DSAs) from an IgM-toIgG could a way to prevent chronic rejection. We evaluated whether belatacept- 
| INTRODUC TI ON
IgG donor-specific anti-HLA antibodies (DSAs) are clear risk factors for allograft failure in organ transplant. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Some patients have IgG
DSAs before transplant and are treated with desensitization regimens to mitigate the risk of acute antibody-mediated rejection and early graft failure. 11, 12 Patients without circulating DSAs before transplant are nonetheless at risk to develop IgG de novo DSAs (dnDSAs), most commonly in the first 2 years posttransplant. 4, [13] [14] [15] In both cases of antibodies present before transplant or newly detected posttransplant, the risk of DSA-associated allograft failure is about 7% in the first year post-DSAs 4,16 By 5 years post-DSAs, approximately 40% of patients experience allograft failure.
Immunologically, IgM DSAs should appear before IgG DSAs and would, therefore, be an earlier sign of potential risk to the allograft. Indeed, a recent single-center study reported that IgMpositive DSAs are commonly detected before IgG DSAs. 17 An interesting and important finding of that study was that the patients presented by MHC class II molecules on B cells. 18, 19 B7 costimulatory signals (B7-1 = CD80, B7-2 = CD86) appear to be essential for antigeninduced antibody production. 20 In kidney transplant, belatacept is a molecule that blocks this costimulatory pathway. It is conceivable that blocking this pathway may prevent IgM-to-IgG conversion.
To investigate the potential differences in IgM-to-IgG conversion in cyclosporine A (CsA) and belatacept treatment groups, we retrospectively conducted HLA Ig isotype analysis testing on patients who participated in the phase 3 belatacept trials (IM103-008 and IM103-027). We then looked to see how the presence of IgM related to subsequent IgG formation and clinical transplant outcomes.
Second, we aimed to confirm the IgG dnDSA analysis of the 2 phase 3 trials. 21 In the overall cohorts of the 2 trials, many patients did not have donor or recipient HLA-DQ typing. In the current analysis, dnDSA formation was investigated in HLA-mismatched patients with complete HLA (including HLA-DQ) typing information.
| ME THODS

| Patient selection and methods
Patients from the phase 3 belatacept trials (n = 1209), BENEFIT or had samples missing at or near the time points discussed in the HLA antibody testing later were excluded (n = 77). A final total of 330 of the 1209 patients were included in the analysis. The demographics of this group are presented in Table 1 .
| HLA tissue typing
HLA typing was performed at each center during the course of the study for HLA-A, -B, -DR, and -DQB1 antigens. Data regarding HLA-DP, -C, or -DQα antigens or antibodies were not included in this report since the antigen typing analysis for these was not conducted in many of the patients. 
| HLA antibody testing
| Study immunosuppression protocols
Most methodology pertaining to the BENEFIT and BENEFIT-EXT trials has been described previously. [22] [23] [24] [25] Both are 3-year, randomized, partially blinded, active-controlled, parallel-group studies in adult patients aged ≥18 years. Primary outcomes were assessed at 12 months posttransplant. The BENEFIT study included recipients of living donor or standard criteria deceased donor kidneys, the latter with an anticipated cold ischemia time of <24 hours.
The BENEFIT-EXT study used an expanded criteria donors definition from the United Network for Organ Sharing (ie, any donor over the age of 60, or a donor over the age of 50 with 2 of the following:
a history of high blood pressure, a creatinine [blood test that shows
kidney function] level ≥1.5, or death resulting from a stroke).
Patients in each study were randomized to receive a more intensive (MI) regimen of belatacept, a less intensive (LI) regimen of belatacept, or a CsA regimen for primary maintenance immunosuppression. Patients were also treated with basiliximab induction, mycophenolate mofetil, and corticosteroids.
| Statistical methods
All statistical analyses were performed by using Stata/MP version 14.2 (College Station, TX). A 2-sided P-value of <.05 was considered statistically significant. Observations between groups were compared by using the Fisher exact or χ 2 test for categorical variables. Unpaired t-test, 1-way ANOVA, or Kruskal-
Wallis test was used for continuous variables. Kaplan-Meier
analysis was used to determine the incidence and probability of survival with a log-rank used to compare groups. Allograft loss was defined as retransplantation or a return to dialysis for ≥56 consecutive days. (27) 31 (26) Living related donor 77 (23) 27 (27) 26 (24) 24 (20) Living unrelated donor 44 (13) 15 (15) 15 (14) 14 (12) Study, n (%) 
| RE SULTS
| Patient characteristics
A total of 330 transplant patients were included in the cohort (n = 213
from BENEFIT and n = 117 from BENEFIT-EXT) ( Table 1) . By treatment group, the numbers of patients were similar (belatacept-LI: n = 102; belatacept-MI: n = 110; and CsA: n = 118). The mean age was 47 years, and the majority of subjects were male (65%) and white (63%). The general patient characteristics, including HLA mismatch and donor type, were similar among the treatment groups. The median follow-up was 7 years for the belatacept groups (both MI and LI) and 3.8 years for the CSA group. By treatment group, there was an equal distribution of patients developing IgM DSAs (Table 1) , although IgM dnDSAs were slightly lower in the belatacept-MI group (11%) versus the CsA and belatacept-LI groups (15% and 17%, respectively).
| IgM
| CsA-treated patients had a higher rate of IgG dnDSA positivity than belatacept treated patients
When looking at the population in our analysis group, we found the overall proportion of IgG-positive DSA cases to be 34% (n = 113). Preexisting IgG DSA-positive rates were similar between groups.
By treatment group, we found that belatacept-treated patients were at a significantly lower risk to develop IgG dnDSAs ( Table 1 ). The
CsA group had the highest proportion of IgG dnDSA-positive cases (34%), followed by the belatacept-MI group and -LI groups (11% and 8%, respectively, P < .001).
| CsA-treated patients had a significantly higher rate of conversion of IgM DSAs to IgG DSAs than did belatacept-treated patients
Of the 50 pretransplant IgM-positive DSA patients, 17 were also The patients with missing typing in A-loci (n = 0), B-loci (n = 1), DR-loci (n = 8), and DQ-loci (n = 58) were not included in percentages. Figure 2B ).
TA B L E 1 (Continued)
DSA
| CsA-treated patients had poorer allograft survival than did belatacept-treated patients
Patients in the 3 groups were compared to evaluate differences in survival by 6 years posttransplant. Allograft survival was significantly greater for the belatacept-MI group compared with the CsAtreated patients (P = .02, Figure 3 IgM-to-IgG conversion analysis sample size was small due to the lack of complete pretransplant typing information. A confirmatory analysis is needed to draw more robust conclusions.
| D ISCUSS I ON
We conclude that, in addition to being a medication free of calcineurin inhibitor (CNI) toxicity, belatacept-based maintenance immunosuppression has the potential to lower the risk to develop IgG-positive dnDSA. This is clinically important given that the main cause of allograft failure in organ transplant today is alloantibodymediated rejection. The combination of the absence of CNI toxicity and minimization of DSA appearance may account for the improved allograft survival observed in the belatacept treatment group.
Immunosuppressive agents that prevent the development of IgGpositive dnDSAs are clearly needed and belatacept may be such an agent. Furthermore, given the deleterious nature of IgG-positive dnDSAs, dnDSA prevention as an endpoint for US Food and Drug Administration approval could be investigated.
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